Close Menu

NEW YORK (GenomeWeb) – OpGen plans to offer $6.5 million of its common stock in a public offering, according to a preliminary prospectus filed with the US Securities and Exchange Commission on Friday.

The company has not priced its offering or said when it plans to make the offering. Net proceeds are expected to be about $5.8 million, it said in its SEC document, and will go toward R&D and regulatory activities in support of OpGen's anticipated 510(k) submission to the US Food and Drug Administration for its Acuitas AMR Gene Panel test and the Acuitas Lighthouse Software.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.